Login / Signup
Cost-effectiveness analysis of recombinant factor IX Fc fusion protein compared with recombinant factor IX for the treatment of moderate-severe to severe hemophilia B in China.
Ting Zhou
Shuyue Wang
Yao Zhang
Runhui Wu
Hongchao Li
Published in:
Pediatric blood & cancer (2023)
Compared with rFIX, rFIXFc appears to be a cost-effective option for the lifetime management of moderate-severe to severe HB patients in China.
Keyphrases
</>
early onset
end stage renal disease
newly diagnosed
chronic kidney disease
high intensity
ejection fraction
drug induced
prognostic factors
replacement therapy
smoking cessation
patient reported